This video briefly summarizes key interim data from the MINERVA study presented at this year’s ARVO congress, held in Seattle, US (Monday 02 May 2016, 09:45-10:00 AM, Program Number 1349). A total of 178 patients were randomized to receive ranibizumab or sham at baseline, and treated pro re nata (PRN). Investigators Lai et al. from the University of Hong Kong reported that ranibizumab had demonstrated superior efficacy versus the sham group, with ranibizumab-treated patients gaining 9.5 ETDRS letters at month 2, and that there were no safety concerns. The investigators concluded that there were visual benefits in treating patients with choroidal neovascularization (CNV) that is not related to age-related macular degeneration (AMD) with ranibizumab.
Ranibizumab in CV pts
Other Perspective
Managing GA in clinical practice: new challenges, new models
With the new treatments for GA, it is important to re-think the management of patients looking at th
The new era in the management of patients with geographic atrophy
Paolo Lanzetta discusses with Baruch Kuppermann about the new treatments for geographic atrophy appr
Euretina 2023 – Controversies and future trends in intravitreal therapies
IVEG instructional course – Euretina 2023Take-home messagesIn this video, the best of our
Home monitoring
Paolo Lanzetta, MD, interviews Anat Loewenstein, MD, on home monitoring, a technology in which her r
Related Articles
